For marking small batches of its vials and infusion bottles efficiently, healthcare company Octapharma relies on a new, automated application system from Schreiner MediPharm. The semi-automatic dispensing system satisfies the pharmaceutical manufacturer’s requirement for a fast, precise, and professional solution enabling the company to label small quantities and diverse containers flexibly, fast, and at consistent levels of quality.
The customized labeling system from Schreiner MediPharm that was designed together with the Schreiner Services competence center enables automated labeling of vials and infusion bottles of different sizes, diameters, and shapes. It can be adjusted individually, allows for fast changeovers, is easy to operate, and requires minimal space due to its compact design. Octapharma can mark small batch sizes and a wide variety of sorts, for instance serving smaller markets, different language versions, or clinical trial drugs reliably, economically, and in a time-saving manner in this way.
The dispensing system can process any glass container, from very small vials with narrow radii to large bottles. Container diameters from a minimum of 15 millimeters to a maximum of 170 millimeters are possible. The height of the bottles to be processed ranges between 35 and 250 millimeters, depending on their shape.
The longstanding customer is already using several of these labeling systems from Schreiner MediPharm. Summing up the benefits of this solution, Brigitta Nehrer, Production Management and Deputy Head of Visual Inspection & Packaging Operations from Octapharma, says, “We are able to label all products from the smallest vials to large bottles efficiently at high and, above all, consistent levels of quality. Compared to previous manual application processes, this reduces the workload of our employees noticeably. As a result, handling of small batch sizes has been professionalized and become clearly more economical."
About Octapharma
Octapharma is a family-owned, global healthcare company headquartered in Lachen, Switzerland, and focused on hematology, immunotherapy, and critical care. Octapharma is one of the largest human protein product manufacturers and develops medicines based on human proteins from human cell lines and human plasma. The company employs more than 9,000 people at six manufacturing sites, has seven preclinical and clinical R+D sites, and is represented in 118 countries.